Key result
Celecoxib significantly improved endothelium-dependent vasodilation compared with placebo (3.3% vs 2.0%, P=0.026) in male patients with severe coronary artery disease.
Why the study?
Does celecoxib improve flow-mediated dilation of the brachial artery in male patients with severe coronary artery disease?
RCT (n=14)
Double-blind
Does celecoxib improve flow-mediated dilation of the brachial artery in male patients with severe coronary artery disease?
Absolute Event Rate: 3.3% vs 2%
p-value: p=0.026
Short-term selective COX-2 inhibition with celecoxib improves endothelial function and reduces markers of inflammation and oxidative stress in men with severe coronary artery disease.
No takes yet. Share an insight, caveat, or question.
Indicates possible short-term endothelial benefit with celecoxib in severe CAD; leaves open effects on clinical outcomes and long-term safety.
Chenevard et al. (2003) conducted an RCT in Coronary artery disease (n=14). Celecoxib vs. Placebo was evaluated on Endothelium-dependent vasodilation (flow-mediated dilation of the brachial artery) (p=0.026). Celecoxib significantly improved endothelium-dependent vasodilation compared with placebo (3.3% vs 2.0%, P=0.026) in male patients with severe coronary artery disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: